Phospholamban gene ablation improves calcium transients but not cardiac function in a heart failure model

Andrzej M. Janczewski, Maliha Zahid, Bonnie H. Lemster, Carol S. Frye, Gregory Gibson, Yoshihiro Higuchi, Evangelia G. Kranias, Arthur M. Feldman, Charles F. McTiernan

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Decreased amplitude and slower kinetics of cardiomyocyte intracellular calcium (Cai2+) transients may underlie the diminished cardiac function observed in heart failure. These alterations occur in humans and animals with heart failure, including the TNF1.6 mouse model, in which heart failure arises from cardiac-specific overexpression of tumor necrosis factor α (TNFα). Objective: Since ablation of phospholamban expression (PLBKO) removes inhibition of the sarcoplasmic reticulum (SR) Ca2+ pump, enhances SR Ca2+ uptake and increases contractility, we assessed whether ablation of phospholamban expression could improve cardiac function, limit remodeling, and improve survival in the TNF1.6 model of heart failure. Methods: We bred PLBKO with TNF1.6 mice and characterized the progeny for survival, cardiac function (echocardiography), cardiac remodeling (hypertrophy, dilation, fibrosis), and Cai2+ transients and contractile function of isolated cardiomyocytes. Results: PLB ablation did not improve survival, cardiac function, or limit cardiac chamber dilation and hypertrophy in TNF1.6 mice (TKO mice). However, contractile function and Ca i2+ transients (amplitude and kinetics) of isolated TKO cardiomyocytes were markedly enhanced. This discordance between unimproved cardiac function, and enhanced Cai2+ cycling and cardiomyocyte contractile parameters may arise from a continued overexpression of collagen and decreased expression of gap junction proteins (connexin 43) in response to chronic TNFα stimulation. Conclusions: Enhancement of intrinsic cardiomyocyte Cai2+ cycling and contractile function may not be sufficient to overcome several parallel pathophysiologic processes present in the failing heart.

Original languageEnglish
Pages (from-to)468-480
Number of pages13
JournalCardiovascular research
Volume62
Issue number3
DOIs
Publication statusPublished - Jun 1 2004

Fingerprint

Cardiac Myocytes
Heart Failure
Calcium
Genes
Sarcoplasmic Reticulum
Survival
Dilatation
Tumor Necrosis Factor-alpha
Connexin 43
Connexins
Cardiomegaly
Hypertrophy
Echocardiography
Fibrosis
Collagen
phospholamban

All Science Journal Classification (ASJC) codes

  • Physiology
  • Cardiology and Cardiovascular Medicine
  • Physiology (medical)

Cite this

Phospholamban gene ablation improves calcium transients but not cardiac function in a heart failure model. / Janczewski, Andrzej M.; Zahid, Maliha; Lemster, Bonnie H.; Frye, Carol S.; Gibson, Gregory; Higuchi, Yoshihiro; Kranias, Evangelia G.; Feldman, Arthur M.; McTiernan, Charles F.

In: Cardiovascular research, Vol. 62, No. 3, 01.06.2004, p. 468-480.

Research output: Contribution to journalArticle

Janczewski, AM, Zahid, M, Lemster, BH, Frye, CS, Gibson, G, Higuchi, Y, Kranias, EG, Feldman, AM & McTiernan, CF 2004, 'Phospholamban gene ablation improves calcium transients but not cardiac function in a heart failure model', Cardiovascular research, vol. 62, no. 3, pp. 468-480. https://doi.org/10.1016/j.cardiores.2004.02.006
Janczewski, Andrzej M. ; Zahid, Maliha ; Lemster, Bonnie H. ; Frye, Carol S. ; Gibson, Gregory ; Higuchi, Yoshihiro ; Kranias, Evangelia G. ; Feldman, Arthur M. ; McTiernan, Charles F. / Phospholamban gene ablation improves calcium transients but not cardiac function in a heart failure model. In: Cardiovascular research. 2004 ; Vol. 62, No. 3. pp. 468-480.
@article{b6801723c5d14389aed218ca4462997c,
title = "Phospholamban gene ablation improves calcium transients but not cardiac function in a heart failure model",
abstract = "Decreased amplitude and slower kinetics of cardiomyocyte intracellular calcium (Cai2+) transients may underlie the diminished cardiac function observed in heart failure. These alterations occur in humans and animals with heart failure, including the TNF1.6 mouse model, in which heart failure arises from cardiac-specific overexpression of tumor necrosis factor α (TNFα). Objective: Since ablation of phospholamban expression (PLBKO) removes inhibition of the sarcoplasmic reticulum (SR) Ca2+ pump, enhances SR Ca2+ uptake and increases contractility, we assessed whether ablation of phospholamban expression could improve cardiac function, limit remodeling, and improve survival in the TNF1.6 model of heart failure. Methods: We bred PLBKO with TNF1.6 mice and characterized the progeny for survival, cardiac function (echocardiography), cardiac remodeling (hypertrophy, dilation, fibrosis), and Cai2+ transients and contractile function of isolated cardiomyocytes. Results: PLB ablation did not improve survival, cardiac function, or limit cardiac chamber dilation and hypertrophy in TNF1.6 mice (TKO mice). However, contractile function and Ca i2+ transients (amplitude and kinetics) of isolated TKO cardiomyocytes were markedly enhanced. This discordance between unimproved cardiac function, and enhanced Cai2+ cycling and cardiomyocyte contractile parameters may arise from a continued overexpression of collagen and decreased expression of gap junction proteins (connexin 43) in response to chronic TNFα stimulation. Conclusions: Enhancement of intrinsic cardiomyocyte Cai2+ cycling and contractile function may not be sufficient to overcome several parallel pathophysiologic processes present in the failing heart.",
author = "Janczewski, {Andrzej M.} and Maliha Zahid and Lemster, {Bonnie H.} and Frye, {Carol S.} and Gregory Gibson and Yoshihiro Higuchi and Kranias, {Evangelia G.} and Feldman, {Arthur M.} and McTiernan, {Charles F.}",
year = "2004",
month = "6",
day = "1",
doi = "10.1016/j.cardiores.2004.02.006",
language = "English",
volume = "62",
pages = "468--480",
journal = "Cardiovascular Research",
issn = "0008-6363",
publisher = "Oxford University Press",
number = "3",

}

TY - JOUR

T1 - Phospholamban gene ablation improves calcium transients but not cardiac function in a heart failure model

AU - Janczewski, Andrzej M.

AU - Zahid, Maliha

AU - Lemster, Bonnie H.

AU - Frye, Carol S.

AU - Gibson, Gregory

AU - Higuchi, Yoshihiro

AU - Kranias, Evangelia G.

AU - Feldman, Arthur M.

AU - McTiernan, Charles F.

PY - 2004/6/1

Y1 - 2004/6/1

N2 - Decreased amplitude and slower kinetics of cardiomyocyte intracellular calcium (Cai2+) transients may underlie the diminished cardiac function observed in heart failure. These alterations occur in humans and animals with heart failure, including the TNF1.6 mouse model, in which heart failure arises from cardiac-specific overexpression of tumor necrosis factor α (TNFα). Objective: Since ablation of phospholamban expression (PLBKO) removes inhibition of the sarcoplasmic reticulum (SR) Ca2+ pump, enhances SR Ca2+ uptake and increases contractility, we assessed whether ablation of phospholamban expression could improve cardiac function, limit remodeling, and improve survival in the TNF1.6 model of heart failure. Methods: We bred PLBKO with TNF1.6 mice and characterized the progeny for survival, cardiac function (echocardiography), cardiac remodeling (hypertrophy, dilation, fibrosis), and Cai2+ transients and contractile function of isolated cardiomyocytes. Results: PLB ablation did not improve survival, cardiac function, or limit cardiac chamber dilation and hypertrophy in TNF1.6 mice (TKO mice). However, contractile function and Ca i2+ transients (amplitude and kinetics) of isolated TKO cardiomyocytes were markedly enhanced. This discordance between unimproved cardiac function, and enhanced Cai2+ cycling and cardiomyocyte contractile parameters may arise from a continued overexpression of collagen and decreased expression of gap junction proteins (connexin 43) in response to chronic TNFα stimulation. Conclusions: Enhancement of intrinsic cardiomyocyte Cai2+ cycling and contractile function may not be sufficient to overcome several parallel pathophysiologic processes present in the failing heart.

AB - Decreased amplitude and slower kinetics of cardiomyocyte intracellular calcium (Cai2+) transients may underlie the diminished cardiac function observed in heart failure. These alterations occur in humans and animals with heart failure, including the TNF1.6 mouse model, in which heart failure arises from cardiac-specific overexpression of tumor necrosis factor α (TNFα). Objective: Since ablation of phospholamban expression (PLBKO) removes inhibition of the sarcoplasmic reticulum (SR) Ca2+ pump, enhances SR Ca2+ uptake and increases contractility, we assessed whether ablation of phospholamban expression could improve cardiac function, limit remodeling, and improve survival in the TNF1.6 model of heart failure. Methods: We bred PLBKO with TNF1.6 mice and characterized the progeny for survival, cardiac function (echocardiography), cardiac remodeling (hypertrophy, dilation, fibrosis), and Cai2+ transients and contractile function of isolated cardiomyocytes. Results: PLB ablation did not improve survival, cardiac function, or limit cardiac chamber dilation and hypertrophy in TNF1.6 mice (TKO mice). However, contractile function and Ca i2+ transients (amplitude and kinetics) of isolated TKO cardiomyocytes were markedly enhanced. This discordance between unimproved cardiac function, and enhanced Cai2+ cycling and cardiomyocyte contractile parameters may arise from a continued overexpression of collagen and decreased expression of gap junction proteins (connexin 43) in response to chronic TNFα stimulation. Conclusions: Enhancement of intrinsic cardiomyocyte Cai2+ cycling and contractile function may not be sufficient to overcome several parallel pathophysiologic processes present in the failing heart.

UR - http://www.scopus.com/inward/record.url?scp=2442501143&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2442501143&partnerID=8YFLogxK

U2 - 10.1016/j.cardiores.2004.02.006

DO - 10.1016/j.cardiores.2004.02.006

M3 - Article

C2 - 15158139

AN - SCOPUS:2442501143

VL - 62

SP - 468

EP - 480

JO - Cardiovascular Research

JF - Cardiovascular Research

SN - 0008-6363

IS - 3

ER -